Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
P/E ratio for Syndax Pharmaceuticals, Inc. (SNDX)
P/E ratio as of 2023: -7.26
According to Syndax Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.26. At the end of 2022 the company had a P/E ratio of -10.76.
P/E ratio history for Syndax Pharmaceuticals, Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -7.26 |
| 2022 | -10.76 |
| 2021 | 45.72 |
| 2020 | -12.57 |
| 2019 | -4.78 |
| 2018 | -1.53 |
| 2017 | -3.03 |
| 2016 | -2.36 |
| 2015 | -8.64 |
| 2014 | -5.81 |
| 2013 | -6.78 |
| 2012 | -84.64 |